Disease-A-Month
Volume 56, Issue 8 , Pages 468-478 , August 2010

Myelodysplastic Syndromes: What a Primary Care Physician Needs to Know

References 

  1. Bennett JM, Komrokji R, Kouides P. The myelodysplastic syndromes. In:  Abeloff MD,  Armitage JO,  Niederhuber JE editor. Clinical Oncology. New York: Churchill Livingstone; 2004;
  2. Rollison DE, Nadia H, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-04, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45–52
  3. Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–1542
  4. Rosing JL, Komrokji RS, Margolin E, et al. In: Anemia in Elderly Hospitalized Veterans: Prevalence, Causes, and Clinical Impact. Ash Annual Meeting Abstracts. 2005;106(11):3756
  5. Park DJ, Koeffler HP. Therapy-related myelodysplastic syndromes. Semin Hematol. 1996;33(3):256–273
  6. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12(12):2527–2534
  7. Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994;12(12):2535–2542
  8. Miller JS, Arthur DC, Litz CE, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83(12):3780–3786
  9. Geddes AA, Bowen DT, Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br J Hæmatol. 1990;76(2):194–202
  10. Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol. 2009;16(2):70–76
  11. Fenaux P, Morel P, Lai JL. Cytogenetics of myelodysplastic syndromes. Semin Hematol. 1996;33(2):127–138
  12. Ebert BL, Jennifer P, Jocelyn B, et al. Identification of RPS14 as the 5Q-syndrome gene by RNA interference screen. Ash Annual Meeting Abstracts. 2007;110(11):1
  13. Guillermo G-M. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008;20(6):705–710
  14. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10(suppl 1):258–269
  15. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias (French-American-British (FAB) co-operative group). Br J Hæmatol. 1976;33(4):451–458
  16. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Hæmatol. 1982;51(2):189–199
  17. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–2302
  18. Komrokji R, Bennett JM. What is “WHO”? (myelodysplastic syndrome classification and prognosis). ASCO Educ Book. 2009;413–419
  19. Greenberg P, Cox C, Lebeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088
  20. Hellstrom-Lindberg E. Update on Supportive Care and New Therapies: Immunomodulatory Drugs, Growth Factors and Epigenetic-Acting Agents. Hematology/The Education Program of the American Society of Hematology. American Society of Hematology; 2005;
  21. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Hæmatol. 1995;89(1):67–71
  22. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. Scandinavian MDS Group A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037–1046
  23. Miller K. Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. Leuk Res. 1998;22(suppl 1):S13–S16
  24. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109(9):1705–1714
  25. Bussel JB, Kuter DJ, George JN, et al. Five hundred and thirty-one, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672–1681
  26. Hagop K, Frank G, Peter G, et al. Effect of Romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Ash Annual Meeting Abstracts. 2008;112:224
  27. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247
  28. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232
  29. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549–557
  30. List A, Dewald G, Bennett J, et al. Myelodysplastic syndrome-003 Study Investigators Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–1465
  31. Sloand EM, Wu CO, Peter G, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505–2511
  32. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579–585
  33. Guillermo S, Benet N, Esperanza S, et al. Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome. Annual ASH Meeting Abstracts. 2008;112(11):640
  34. List AF, Baer MR, Steensma D, et al. Deferasirox (ICL670; Exjade(R)) reduces Serum Ferritin (SF) and Labile Plasma Iron (LPI) in patients with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstracts. 2007;110(11):1470
  35. Christian R, Sabine B, Dominique V, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients (A Prospective Analysis by the GFM). Annual ASH Meeting Abstracts. 2007;110(11):249
  36. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008;83(11):858–861

PII: S0011-5029(10)00047-7

doi: 10.1016/j.disamonth.2010.03.007

Disease-A-Month
Volume 56, Issue 8 , Pages 468-478 , August 2010

Article Tools

* Image Usage & Resolution